These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 3447435)

  • 1. A purification method by uncoated charcoal.
    Cerulli N; Politi L; D'Angelo AR; Scandurra R
    Adv Exp Med Biol; 1987; 223():193-6. PubMed ID: 3447435
    [No Abstract]   [Full Text] [Related]  

  • 2. Improvement of continuous arteriovenous hemofiltration (CAVH) and hemofiltration (HF) efficiency by adding hemoperfusion (HP).
    Marangoni R; Civardi F; Masi F; Avanzi C; Savino R; Manfredi A; Cimino R
    Biomater Artif Cells Artif Organs; 1990; 18(4):541-8. PubMed ID: 2285819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Our experience with combined hemodialysis-hemoperfusion treatment in chronic uremia.
    Splendiani G; Albano V; Tancredi M; Daniele M; Pignatelli F
    Biomater Artif Cells Artif Organs; 1987; 15(1):175-81. PubMed ID: 3449135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemofiltration-induced serum modifications in the pattern of larger molecules.
    David S; Barani R; Buzio C; Arisi L; Quaretti P
    Adv Exp Med Biol; 1987; 223():281-6. PubMed ID: 3447447
    [No Abstract]   [Full Text] [Related]  

  • 5. [A comparison of the efficiency of eliminating middle-weight molecules and myoinositol from plasma during hemoperfusion and hemodialysis in cases of chronic uremia].
    Trznadel K; Kidawa Z; Walasek L; Lutz W
    Pol Tyg Lek; 1978 Feb; 33(7):257-9. PubMed ID: 758030
    [No Abstract]   [Full Text] [Related]  

  • 6. [The effect of hemoperfusion through activated charcoal on middle molecular substances in the plasma during a long-term dialysis program].
    Mydlík M; Dzúrik R; Derzsiová K; Spustová V
    Cas Lek Cesk; 1983 Dec; 122(51):1573-6. PubMed ID: 6652672
    [No Abstract]   [Full Text] [Related]  

  • 7. Uremic toxins.
    Ringoir S; Schoots A; Vanholder R
    Kidney Int Suppl; 1988 Mar; 24():S4-9. PubMed ID: 3283412
    [No Abstract]   [Full Text] [Related]  

  • 8. Adsorption of Protein-Bound Uremic Toxins Using Activated Carbon through Direct Hemoperfusion in vitro.
    Yamamoto S; Ito T; Sato M; Goto S; Kazama JJ; Gejyo F; Narita I
    Blood Purif; 2019; 48(3):215-222. PubMed ID: 31055586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessments of clinical trials of charcoal hemoperfusion in uremic patients.
    Chang TM
    Clin Nephrol; 1979 Feb; 11(2):111-9. PubMed ID: 378489
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hemosorption as a treatment method for uremic complications].
    Pilotovich VS; Ostapenko VA; Shilaĭ LM; Kirkovskiĭ VV; Nikolaĭchik VV
    Klin Med (Mosk); 1982 Apr; 60(4):77-80. PubMed ID: 7098397
    [No Abstract]   [Full Text] [Related]  

  • 11. Aluminum removal with hemodialysis, hemofiltration and charcoal hemoperfusion in uremic patients after desferrioxamine infusion. A comparison of efficiency.
    Weiss LG; Danielson BG; Fellström B; Wikström B
    Nephron; 1989; 51(3):325-9. PubMed ID: 2918944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paired filtration-dialysis (PFD): a separate convective-diffusive system for extracorporeal blood purification in uraemic patients.
    Ghezzi PM; Zucchelli P; Ringoir S; Nigrelli S; Santoro A; Gervasio R; Sanz Moreno C; Vanholder R; Botella J
    Adv Exp Med Biol; 1987; 223():267-75. PubMed ID: 3328955
    [No Abstract]   [Full Text] [Related]  

  • 13. Adequacy of hemoperfusion for blood purification in uremia.
    Chang TM
    Contrib Nephrol; 1993; 103():10-25. PubMed ID: 8354053
    [No Abstract]   [Full Text] [Related]  

  • 14. Adsorption of Protein-Bound Uremic Toxins Through Direct Hemoperfusion With Hexadecyl-Immobilized Cellulose Beads in Patients Undergoing Hemodialysis.
    Yamamoto S; Sato M; Sato Y; Wakamatsu T; Takahashi Y; Iguchi A; Omori K; Suzuki Y; Ei I; Kaneko Y; Goto S; Kazama JJ; Gejyo F; Narita I
    Artif Organs; 2018 Jan; 42(1):88-93. PubMed ID: 28703401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uremic middle molecules exist and are biologically active.
    Bergström J; Fürst P; Zimmerman L
    Clin Nephrol; 1979 May; 11(5):229-38. PubMed ID: 455821
    [No Abstract]   [Full Text] [Related]  

  • 16. Continuous measurement of DTPA-clearance in extracorporeal detoxification circuits.
    Falkenhagen D; Ahrenholz P; Roy T; Esther G; Kiencke H; Klinkmann H
    Artif Organs; 1981; 4 Suppl():166-8. PubMed ID: 7295085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum middle molecules in uremia.
    Buzio C; Manari A; Calderini C; Montagna G; Migone L
    Artif Organs; 1981; 4 Suppl():143-50. PubMed ID: 7295081
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of chromatographic fractions of blood ultrafiltrates of patients with chronic uremia on the fibrinolytic activity]].
    Popławski A; Myśliwiec M; Soszka J
    Pol Tyg Lek; 1990 Oct 1-8; 45(40-41):810-3. PubMed ID: 2096374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perfusion of uremic blood ultrafiltrate on uncoated charcoal.
    Politi L; Cerulli N; D'Angelo AR; Scandurra R
    Artif Organs; 1989 Jun; 13(3):246-51. PubMed ID: 2764765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemoperfusion with uncoated amberlite XE-336 resin in normal and uremic dogs.
    Rosenbaum JL; Kramer MS; Raja R
    Nephron; 1978; 21(1):27-37. PubMed ID: 662054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.